Browsing Tag
Shield Therapeutics plc
1 post
Shield Therapeutics (AIM: STX) cuts H1 loss 76% as revenue rises 42% to $30.4m
Group revenue reached US$30.4 million and the loss narrowed to US$2.3 million, but Accrufer prescription growth of 21% translated into only 5% US product-revenue growth as net pricing weakened.